Michael Andriole

Directeur Général chez CHIMERIX, INC.

Fortune : 398 296 $ au 30/04/2024

51 ans

Health Technology

Consumer Services

Postes actifs de Michael Andriole

Sociétés	Poste	Début	Fin
CHIMERIX, INC.	Directeur/Membre du Conseil	01/08/2023	-
	Directeur Général	01/08/2023	-
	President	01/08/2023	-
	Directeur Financier/CFO	31/05/2019	01/08/2023
	Corporate Officer/Principal	08/04/2019	31/05/2019

Sociétés	Poste	Début	Fin
ENDOCYTE, INC.	Directeur Financier/CFO	21/02/2017	01/12/2018
ELI LILLY AND COMPANY	Corporate Officer/Principal	01/08/2006	01/02/2017

Kelley School of Business	Masters Business Admin
Williams College of Business	Undergraduate Degree

Internationale

Etats-Unis

Opérationnelle

Director of Finance/CFO	2
Corporate Officer/Principal	2
Undergraduate Degree	1

Sectorielle

Health Technology	4
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
ELI LILLY AND COMPANY	Health Technology
CHIMERIX, INC.	Health Technology

Entreprise privées	1
Endocyte, Inc. Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.	Health Technology

Entreprise privées

Health Technology